The anorexiants market delivers several benefits, primarily aiding weight management and obesity treatment. These medications effectively suppress appetite, helping individuals control caloric intake and promote weight loss. Additionally, they can enhance metabolic processes and support lifestyle changes, further contributing to healthier outcomes. Among the market segments, appetite suppressants constitute the dominating category. These drugs, such as phentermine, are widely prescribed due to their efficacy in curbing hunger and assisting in weight reduction, making them a prominent choice in the anorexiants market.
Access full Report @ https://www.databridgemarketresearch.com/jp/reports/us-anorexiants-market
Data Bridge Market Research analyses that the U.S. Anorexiants Market tends to be around 4% in the forecast period of 2023-2030. The market value is USD 217.8 million in 2022, and it will grow up to USD 298.07 million by 2030. Sedentary lifestyles, characterized by limited physical activity, coupled with unhealthy dietary habits, lead to calorie imbalances, promoting weight gain. This escalating concern underscores the growing necessity for effective weight management solutions to counteract these detrimental lifestyle factors.
Key Findings of the Study
Regulatory approvals are expected to drive the market's growth rate
Regulatory approvals play a pivotal role in the growth of the anorexiants market. When regulatory bodies validate the safety and efficacy of new anorexiant drugs, it instills confidence among healthcare providers and patients. These approvals signify that the medications meet stringent quality and safety standards, making them a trusted choice for weight management. This not only expands treatment options but also fosters market growth as physicians are more such asly to prescribe approved drugs, driving overall market demand.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Drug Class (Catecholamines Anorexiants, Serotonin Anorexiants), Drug Type (Generics, Branded), Applications (Weight Loss, Obesity, Attention Deficit Hyperactivity Disorder (ADHD), Dravet Syndrome), Prescription Mode (Prescription, OTC), Route of Administration (Oral, Parenteral), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S.
|
|
Market Players Covered
|
F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Sanofi (France), Pfizer Inc. (U.S.), Novartis AG (Switzerland), Merck & Co., Inc. (U.S.), Johnson & Johnson Private Limited (U.S.), Aurobindo Pharma (India), Cipla Inc. (U.S.), Lannett (U.S.), Bausch Health Companies Inc. (Canada), Sun Pharmaceutical Industries Ltd. (India), Novo Nordisk A/S (Denmark), Currax Pharmaceuticals LLC (U.S.), Eisai Co., Ltd. (Japan), Merck & Co., Inc. (U.S.), Par Pharmaceutical (U.S.)
|
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Segment Analysis:
The U.S. anorexiants market is segmented on the basis of drug class, indication, route of administration, applications, end user, and distribution channel.
- On the basis of drug class, the U.S. anorexiants market is segmented into catecholamines anorexiants, and serotonin anorexiants.
- On the basis of indication, the U.S. anorexiants market is segmented into generics, and branded.
- On the basis of route of administration, the U.S. anorexiants market is segmented into oral, and parenteral.
- On the basis of applications, the U.S. anorexiants market is segmented into weight loss, obesity, attention deficit hyperactivity disorder (ADHD), and dravet syndrome.
- On the basis of end user, the U.S. anorexiants market is segmented into hospitals, homecare, speciality centres, and others.
- On the basis of distribution channel, the U.S. anorexiants market is segmented into hospital pharmacy, online pharmacy, and retail pharmacy.
Major Players
Data Bridge Market Research recognizes the following companies as the U.S. anorexiants market players in U.S. anorexiants market are F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Sanofi (France), Pfizer Inc. (U.S.), Novartis AG (Switzerland), Merck & Co., Inc. (U.S.), Johnson & Johnson Private Limited (U.S.), Aurobindo Pharma (India), Cipla Inc. (U.S.), Lannett (U.S.).
Market Development
- In 2019, Currax Pharmaceuticals LLC acquired Nalpropion Pharmaceuticals, securing global rights to Contrave, a leading prescription medication for weight loss in both the USA and Europe. This acquisition enabled Currax Pharmaceuticals to expand its portfolio and solidify its position in the weight management pharmaceutical market, capitalizing on Contrave's established presence as a trusted solution for individuals seeking to address obesity and achieve healthier lifestyles.
For more detailed information about the U.S. anorexiants market report, click here – https://www.databridgemarketresearch.com/jp/reports/us-anorexiants-market
